卓翼科技(002369.SZ):實控人擬籌劃公司控制權變更事項 明起停牌
格隆匯 3 月 23日丨卓翼科技(002369.SZ)公佈,公司於2021年3月23日收到公司控股股東、實際控制人夏傳武出具的《關於籌劃上市公司控制權變更事項的通知》,獲悉其擬籌劃公司控制權變更的相關事項,具體方案擬包括非公開發行股票和其所持全部或部分股份的表決權委託等,交易完成後交易對方將獲得公司20%-30%表決權,具體方案以各方簽署的相關協議為準。前述事項可能導致公司控制權發生變更。此次交易對方所屬行業為基礎設施等行業,此次交易相關事項尚需有權部門進行事前審批。
經公司向深圳證券交易所申請,公司股票自2021年3月24日開市起停牌,預計停牌時間不超過5個交易日。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.